Global Drug R&D Express (Jun. 2023)

Based on the latest data from PatSnap Synapse, we has released the "Global Drug R&D Express (May 2023)". The report includes a total of 75 drugs consisting of: ◉ 14 drugs first approved globally: 7Small molecule drug (SMD), 1 Monoclonal antibody(mAb), 1 Enzyme, 1 CAR-T, 1 Fc fragment, 1 Cell therapy, 1 Adeno-associated virus gene therapy 1 traditional Chinese medicine.◉ 58 drugs under Expedited Review pathways worldwide: 32 Orphan Drug designation, 12 Fast Track designation, 9 Priority review, 4 Breakthrough Therapy designation, 2 Accelerated Approval, 1 Qualified Infectious Disease Product, 1 PRIME. The report also highlights 5 first approved drugs and 6 Expedited Review Pathway drugs providing a detailed interpretation of the drugs from multiple aspects such as basic information, R&D status, technical barriers, mechanisms of action, clinical trials, and competitive landscape.